Biomedical research institute
     
    You are here: Home / Institute / News / The Institut Cochin and the team of Ralf Jockers contribute to anti-SARS-CoV-2 drug identification

    The Institut Cochin and the team of Ralf Jockers contribute to anti-SARS-CoV-2 drug identification

    •  

    The Institut Cochin and the team of Ralf Jockers contribute to anti-SARS-CoV-2 drug identification in the European project EXSCALATE4CoV

     

    Escalate4CoV (E4C) is a public-private consortium supported by the European Commission’s Horizon 2020 tender for projects to counter the COVID-19 pandemic.

    At the core of E4C is Exscalate (EXaSCale smArt pLatform Against paThogEns), at present the most powerful and cost-efficient intelligent supercomputing platform in the world for in silico drug design. Exscalate has a "chemical library" of 500 billion molecules and a processing capacity of more than 3 million molecules per second. Coupling this capability with multiple high throughput biochemical and phenotypic screenings, E4C allows rapid identification of safe in man drugs. Its aim is twofold: identify molecules capable of targeting SARS-CoV-2 and develop a tool effective for countering future pandemics to be consolidated over time.

    The team directed by Ralf Jockers contributes to the project by suppling a diversity of compounds for testing against SARS-CoV-2. Once tested the results will be readily made available to the scientific community through the dedicated Exscalate data platform. 

     

    Researcher Contact

     

    Further information

    https://www.exscalate4cov.eu/league.html